DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on October 23, 2008; DOI: 10.1124/dmd.108.022483


0090-9556/09/3701-187-202$20.00
DMD 37:187-202, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.022483v1
37/1/187    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, H.
Right arrow Articles by Pang, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, H.
Right arrow Articles by Pang, K. S.

Disparity in Intestine Disposition between Formed and Preformed Metabolites and Implications: A Theoretical Study

Huadong Sun, and K. Sandy Pang

Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada

Metabolite in safety testing has been proposed for toxicity assessments. The question of how exposure of the synthetic metabolite compared with that of the formed metabolite was appraised kinetically by using physiologically based pharmacokinetic models, the (traditional) physiological model (TM), and segregated flow (SFM) models. The SFM differs from the TM and describes a partial (~10% total) intestinal flow that perfuses the absorptive, metabolic, and secretory enterocyte layer to account for the higher extent of metabolism observed with oral versus systemic dosing of drugs. Theoretical solutions for the areas under the curve (AUC) of the formed metabolite after oral and intravenous administration of the precursor (AUC{mi,P}) and preformed, synthetic metabolite (AUC{pmi}) showed identical AUCiv{mi,P}, AUCpo{mi,P}, and AUCpo{pmi} for both the TM and SFM, whereas a larger AUCiv{pmi} existed for the SFM. The AUC{pmi} was influenced by metabolite parameters only: binding, absorptive (ka{mi}) and luminal degradation (kg{mi}) constants, intrinsic clearances for metabolism (CLint,met,I{mi}), apical efflux (CLint,sec,I{mi}), and basolateral transfer (CLd1{mi} and CLd2{mi}) for the metabolite. By contrast, the AUC{mi,P} was influenced additionally by precursor parameters: rate constants ka and kg, and CLint,met,I and CLint,sec,I, but not the basolateral transfer clearances. The drug parameters: CLint,met,I and ka increased whereas CLint,sec,I decreased AUC{mi,P}, and the effect of secretion was counterbalanced by reabsorption with high ka values. The simulated time courses for the metabolites and the AUC{pmi} and AUC{mi,P} resulting from intravenous and oral routes of administration of preformed metabolite and precursor differed, inferring that the kinetics of the preformed and formed metabolites are not identical.


Address correspondence to: Dr. K. Sandy Pang, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, ON M5S 3M2 Canada. E-mail: ks.pang{at}utoronto.ca







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.